A Safety and Efficacy Study of Patients Requiring Sedation for Elective Awake Fiberoptic Intubation.
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine versus placebo used for sedation during elective awake fiberoptic intubation.
| Condition | Intervention | Phase |
|---|---|---|
|
Awake Fiberoptic Intubation |
Drug: Dexmedetomidine Drug: Midazolam |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Dexmedetomidine Used for Sedation During Elective Awake Fiberoptic Intubation |
- The percentage of subjects requiring rescue midazolam to achieve and/or maintain
- proper sedation levels throughout the study drug infusion.
- Total dose of rescue midazolam required to achieve and/or maintain target sedation
- levels; percentage of subjects requiring additional rescue medications other
- than midazolam to achieve and/or maintain target sedation levels;
- anesthesiologist assessment of ease of subject care; and subject recall and
- satisfaction assessed 24 hours post study drug.
| Estimated Enrollment: | 100 |
| Study Start Date: | August 2006 |
| Study Completion Date: | March 2007 |
An awake fiberoptic intubation is indicated for any patient with an anticipated difficult airway because of their anatomy, airway trauma, morbid obesity, or unstable cervical spine injuries. An awake fiberoptic intubation in a non-sedated patient can be extremely stimulating, uncomfortable, and unpleasant. The clinician must focus on maintaining spontaneous breathing, hemodynamic stability, and the patient's comfort. The term "awake" fiberoptic intubation is used to distinguish this procedure from fiberoptic intubations performed under general anesthesia. Although patients may be sedated for "awake" fiberoptic intubation, they need to be responsive and capable of maintaining their own airway without assistance. Vital components of a successful awake fiberoptic intubation include an anesthesiologist experienced in this technique, adequate topicalization of the airway, and a sedated yet cooperative subject.
Benzodiazepines, combined with opioid, are commonly used for anxiolysis and/or analgesia during awake fiberoptic intubations.
Dexmedetomidine has sympatholytic, sedative, analgesic, and anxiolytic effects that attenuate the catecholamine response to perioperative stress. Dexmedetomidine sedates patients by decreasing sympathetic activity and the level of arousal. Furthermore, dexmedetomidine has been found to facilitate a decrease in salivary secretion, a desirable effect during fiberoptic intubations.
An estimated 100 subjects (50 DEX, 50 PBO) scheduled for an elective awake fiberoptic intubation because of a potentially difficult airway will be randomized prior to intubation at approximately 18 investigative sites.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adult (18 years of age);
- ASA score I - IV inclusive;
- Requiring awake fiberoptic (oral or nasal) intubation because of anticipated difficult airway
Exclusion Criteria:
- Previous exposure to any experimental drug within 30 days prior to study drug administration;
- Central nervous system (CNS) disease with an anticipated increased intracranial pressure or cerebrospinal fluid (CSF) leak;
- Uncontrolled seizure disorder and/or known psychiatric illness that could confound a normal response to sedative treatment;
- Presence of acute alcohol intoxication;
- Current (within 14 days of study entry) treatment with an 2-agonist or antagonist;
- Subject for whom benzodiazepines, DEX or other 2- agonists are contraindicated;
- Subject received an IV or PO opioid within one hour or intramuscularly within four hours of the start of study drug administration;
- Subject has acute unstable angina, laboratory confirmed acute myocardial infarction within the past 6 weeks, heart rate <50 bpm, systolic blood pressure (SBP) <90 mmHg, or complete heart block unless they have a pacemaker.
- Subject has elevated SGPT (ALT) and/or SGOT (AST) values of > 2 times the upper limit of normal (ULN).
- Subject has any other condition or factor which, in the Investigator's opinion, might increase the risk to the subject.
Contacts and Locations| United States, Alabama | |
| Birmingham, Alabama, United States | |
| United States, California | |
| Loma Linda, California, United States | |
| United States, Florida | |
| Miami, Florida, United States | |
| United States, Illinois | |
| Chicago, Illinois, United States | |
| United States, Kansas | |
| Kansas City, Kansas, United States | |
| United States, Minnesota | |
| Rochester, Minnesota, United States | |
| United States, New York | |
| New York, New York, United States | |
| United States, Ohio | |
| Cleveland, Ohio, United States | |
| Columbus, Ohio, United States | |
| United States, Pennsylvania | |
| Allentown, Pennsylvania, United States | |
| United States, South Carolina | |
| Charleston, South Carolina, United States | |
| United States, Texas | |
| Dallas, Texas, United States | |
| Houston, Texas, United States | |
| Temple, Texas, United States | |
| United States, Wisconsin | |
| Milwaukee, Wisconsin, United States | |
More Information
No publications provided by Hospira, Inc.
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| ClinicalTrials.gov Identifier: | NCT00383890 History of Changes |
| Obsolete Identifiers: | NCT00411775 |
| Other Study ID Numbers: | 2005-006 |
| Study First Received: | October 2, 2006 |
| Last Updated: | October 8, 2007 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Hospira, Inc.:
|
American Society of Anesthesiologists (ASA) Mallampati Score Ramsay Sedation Scale (RSS) |
Additional relevant MeSH terms:
|
Midazolam Dexmedetomidine Adjuvants, Anesthesia Central Nervous System Agents Therapeutic Uses Pharmacologic Actions Anti-Anxiety Agents Tranquilizing Agents Central Nervous System Depressants Physiological Effects of Drugs Psychotropic Drugs Hypnotics and Sedatives Anesthetics, Intravenous Anesthetics, General |
Anesthetics GABA Modulators GABA Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Analgesics, Non-Narcotic Analgesics Sensory System Agents Peripheral Nervous System Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists Adrenergic Agonists Adrenergic Agents |
ClinicalTrials.gov processed this record on May 16, 2013